Medication info
Lozazin Plus Tablet

Lozazin Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
For domestic use: 30 tablets/bottle, 300 tablets/bottle For export: 30 tablets/bottle, 30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 200708264 · Notified 2007.07.16 · Insurance code 648500610

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Combination therapy with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Administration to patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration to patients with hepatic impairment requiring dose adjustment is not recommended, because the initial dose of losartan potassium for such patients, 25 mg, cannot be administered using this medicine.
Child dose
○ Children (under 18 years) Since there is no experience of use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension whose blood pressure is not sufficiently controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. In general, the maximum blood pressure-lowering effect occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the expected effect is not achieved with monotherapy. 1. Replacement therapy: Combination therapy with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or higher. Administration to patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration to patients with hepatic impairment requiring dose adjustment is not recommended, because the initial dose of losartan potassium for such patients, 25 mg, cannot be administered using this medicine.

Child dose

○ Children (under 18 years) Since there is no experience of use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication may cause serious harm to the fetus during pregnancy, and it should not be taken by women who are pregnant or may become pregnant. Patients with allergic reactions to this medication, certain kidney dysfunctions, liver dysfunctions, electrolyte imbalances, and certain genetic diseases should also not take this medication. Patients with excessively low blood pressure or abnormalities in renal blood vessels, liver disease patients, patients with diabetes, etc., should take this medication with caution, and the risk of skin cancer may increase, so skin condition should be regularly monitored. During treatment, regular checks of blood pressure, kidney function, electrolyte levels, etc., should be performed to ensure there are no abnormalities, particularly potassium levels. This medication may interact with other drugs, so if you are taking other medications, you must consult your doctor or pharmacist. Caution is required while driving or operating machinery, as dizziness or drowsiness may occur. In case of overdose, symptoms such as hypotension or cardiac arrhythmias may appear, and immediate medical assistance should be sought. Keep out of reach of children, and store in the original container to maintain quality.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 130 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin detachment
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • limb pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle stiffness
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • hyperesthesia
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste abnormalities
  • tinnitus
  • erectile dysfunction
  • nocturnal enuresis
  • frequency of urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsion
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • hemolytic anemia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasm
  • agitation
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrosis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylaxis
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly sealed container to block light. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

For domestic use: 30 tablets/bottle, 300 tablets/bottle For export: 30 tablets/bottle, 30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.